AMARIN CORP PLC\UK — Form 8-K
Filed October 28, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 48/100
What the filing says
Amarin reported Q3 2026 net income of $0.245M (vs. loss of $7.738M in Q3 2025), driven by $70M in completed cost-saving initiatives and 44% operating expense reduction. Total revenue declined 20% YoY to $39.6M (U.S. product revenue down 30% due to generic competition; Rest-of-World up 29%), but European VAZKEPA in-market demand surged 68% YoY through Recordati partnership. Cash position strengthened to $323.4M with zero debt; inventory normalized to $158.9M. Company exploring IPE for new therapeutic applications (colorectal cancer metastases) with patent protection through 2039.
Why this rating
Profitability milestone and strong cost execution meaningful for turnaround; however, core product revenue decline (20% YoY) and U.S. market share pressure (-30%) from generics offset gains. European growth and cash runway are positive but dependent on partner execution outside direct control. Modest relative to $334.7M market cap.
See more from October 28, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.